Intensive	O
social	O
cognitive	B:C0009244
treatment	I:C0009244
(	O
can	O
do	O
treatment	O
)	O
with	O
participation	O
of	O
support	O
partners	O
in	O
persons	O
with	O
relapsing	O
remitting	I:C0751967
multiple	I:C0751967
sclerosis	I:C0751967
:	O
observation	O
of	O
improved	O
self	O
-	I:C0600564
efficacy	I:C0600564
,	O
quality	O
of	O
life	O
,	O
anxiety	O
and	O
depression	O
1	O
year	O
later	O
.	O

Intensive	O
social	O
cognitive	O
treatment	I:C0009244
(	O
can	O
do	O
treatment	O
)	O
with	O
participation	O
of	O
support	O
partners	B:C3887537
in	O
persons	O
with	O
relapsing	O
remitting	I:C0751967
multiple	I:C0751967
sclerosis	I:C0751967
:	O
observation	O
of	O
improved	O
self	O
-	I:C0600564
efficacy	I:C0600564
,	O
quality	O
of	O
life	O
,	O
anxiety	O
and	O
depression	O
1	O
year	O
later	O
.	O

Intensive	O
social	O
cognitive	O
treatment	I:C0009244
(	O
can	O
do	O
treatment	O
)	O
with	O
participation	O
of	O
support	O
partners	O
in	O
persons	B:C0027361
with	O
relapsing	O
remitting	I:C0751967
multiple	I:C0751967
sclerosis	I:C0751967
:	O
observation	O
of	O
improved	O
self	O
-	I:C0600564
efficacy	I:C0600564
,	O
quality	O
of	O
life	O
,	O
anxiety	O
and	O
depression	O
1	O
year	O
later	O
.	O

Intensive	O
social	O
cognitive	O
treatment	I:C0009244
(	O
can	O
do	O
treatment	O
)	O
with	O
participation	O
of	O
support	O
partners	O
in	O
persons	O
with	O
relapsing	B:C0751967
remitting	I:C0751967
multiple	I:C0751967
sclerosis	I:C0751967
:	O
observation	O
of	O
improved	O
self	O
-	I:C0600564
efficacy	I:C0600564
,	O
quality	O
of	O
life	O
,	O
anxiety	O
and	O
depression	O
1	O
year	O
later	O
.	O

Intensive	O
social	O
cognitive	O
treatment	I:C0009244
(	O
can	O
do	O
treatment	O
)	O
with	O
participation	O
of	O
support	O
partners	O
in	O
persons	O
with	O
relapsing	O
remitting	I:C0751967
multiple	I:C0751967
sclerosis	I:C0751967
:	O
observation	B:C0700325
of	O
improved	O
self	O
-	I:C0600564
efficacy	I:C0600564
,	O
quality	O
of	O
life	O
,	O
anxiety	O
and	O
depression	O
1	O
year	O
later	O
.	O

Intensive	O
social	O
cognitive	O
treatment	I:C0009244
(	O
can	O
do	O
treatment	O
)	O
with	O
participation	O
of	O
support	O
partners	O
in	O
persons	O
with	O
relapsing	O
remitting	I:C0751967
multiple	I:C0751967
sclerosis	I:C0751967
:	O
observation	O
of	O
improved	B:C0184511
self	O
-	I:C0600564
efficacy	I:C0600564
,	O
quality	O
of	O
life	O
,	O
anxiety	O
and	O
depression	O
1	O
year	O
later	O
.	O

Intensive	O
social	O
cognitive	O
treatment	I:C0009244
(	O
can	O
do	O
treatment	O
)	O
with	O
participation	O
of	O
support	O
partners	O
in	O
persons	O
with	O
relapsing	O
remitting	I:C0751967
multiple	I:C0751967
sclerosis	I:C0751967
:	O
observation	O
of	O
improved	O
self	B:C0600564
-	I:C0600564
efficacy	I:C0600564
,	O
quality	O
of	O
life	O
,	O
anxiety	O
and	O
depression	O
1	O
year	O
later	O
.	O

Intensive	O
social	O
cognitive	O
treatment	I:C0009244
(	O
can	O
do	O
treatment	O
)	O
with	O
participation	O
of	O
support	O
partners	O
in	O
persons	O
with	O
relapsing	O
remitting	I:C0751967
multiple	I:C0751967
sclerosis	I:C0751967
:	O
observation	O
of	O
improved	O
self	O
-	I:C0600564
efficacy	I:C0600564
,	O
quality	O
of	O
life	O
,	O
anxiety	B:C0003467
and	O
depression	O
1	O
year	O
later	O
.	O

Intensive	O
social	O
cognitive	O
treatment	I:C0009244
(	O
can	O
do	O
treatment	O
)	O
with	O
participation	O
of	O
support	O
partners	O
in	O
persons	O
with	O
relapsing	O
remitting	I:C0751967
multiple	I:C0751967
sclerosis	I:C0751967
:	O
observation	O
of	O
improved	O
self	O
-	I:C0600564
efficacy	I:C0600564
,	O
quality	O
of	O
life	O
,	O
anxiety	O
and	O
depression	B:C0011570
1	O
year	O
later	O
.	O

In	O
persons	B:C0027361
with	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
self	O
-	I:C0600564
efficacy	I:C0600564
positively	O
affects	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
and	O
physical	O
activity	O
.	O

In	O
persons	O
with	O
multiple	B:C0026769
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
self	O
-	I:C0600564
efficacy	I:C0600564
positively	O
affects	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
and	O
physical	O
activity	O
.	O

In	O
persons	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	B:C0026769
sclerosis	I:C0026769
)	O
self	O
-	I:C0600564
efficacy	I:C0600564
positively	O
affects	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
and	O
physical	O
activity	O
.	O

In	O
persons	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
self	B:C0600564
-	I:C0600564
efficacy	I:C0600564
positively	O
affects	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
and	O
physical	O
activity	O
.	O

In	O
persons	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
self	O
-	I:C0600564
efficacy	I:C0600564
positively	B:C1446409
affects	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
and	O
physical	O
activity	O
.	O

In	O
a	O
previous	O
study	O
we	O
observed	O
that	O
6	O
months	O
after	O
an	O
intensive	O
3	O
-	O
day	O
social	O
cognitive	B:C0009244
treatment	I:C0009244
(	O
Can	O
Do	O
treatment	O
)	O
with	O
the	O
participation	O
of	O
support	O
partners	O
,	O
self	O
-	I:C0600564
efficacy	I:C0600564
and	O
HRQoL	O
had	O
improved	O
in	O
persons	O
with	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
(	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
)	O
.	O

In	O
a	O
previous	O
study	O
we	O
observed	O
that	O
6	O
months	O
after	O
an	O
intensive	O
3	O
-	O
day	O
social	O
cognitive	O
treatment	I:C0009244
(	O
Can	O
Do	O
treatment	O
)	O
with	O
the	O
participation	O
of	O
support	O
partners	B:C3887537
,	O
self	O
-	I:C0600564
efficacy	I:C0600564
and	O
HRQoL	O
had	O
improved	O
in	O
persons	O
with	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
(	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
)	O
.	O

In	O
a	O
previous	O
study	O
we	O
observed	O
that	O
6	O
months	O
after	O
an	O
intensive	O
3	O
-	O
day	O
social	O
cognitive	O
treatment	I:C0009244
(	O
Can	O
Do	O
treatment	O
)	O
with	O
the	O
participation	O
of	O
support	O
partners	O
,	O
self	B:C0600564
-	I:C0600564
efficacy	I:C0600564
and	O
HRQoL	O
had	O
improved	O
in	O
persons	O
with	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
(	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
)	O
.	O

In	O
a	O
previous	O
study	O
we	O
observed	O
that	O
6	O
months	O
after	O
an	O
intensive	O
3	O
-	O
day	O
social	O
cognitive	O
treatment	I:C0009244
(	O
Can	O
Do	O
treatment	O
)	O
with	O
the	O
participation	O
of	O
support	O
partners	O
,	O
self	O
-	I:C0600564
efficacy	I:C0600564
and	O
HRQoL	O
had	O
improved	B:C0184511
in	O
persons	O
with	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
(	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
)	O
.	O

In	O
a	O
previous	O
study	O
we	O
observed	O
that	O
6	O
months	O
after	O
an	O
intensive	O
3	O
-	O
day	O
social	O
cognitive	O
treatment	I:C0009244
(	O
Can	O
Do	O
treatment	O
)	O
with	O
the	O
participation	O
of	O
support	O
partners	O
,	O
self	O
-	I:C0600564
efficacy	I:C0600564
and	O
HRQoL	O
had	O
improved	O
in	O
persons	B:C0027361
with	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
(	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
)	O
.	O

In	O
a	O
previous	O
study	O
we	O
observed	O
that	O
6	O
months	O
after	O
an	O
intensive	O
3	O
-	O
day	O
social	O
cognitive	O
treatment	I:C0009244
(	O
Can	O
Do	O
treatment	O
)	O
with	O
the	O
participation	O
of	O
support	O
partners	O
,	O
self	O
-	I:C0600564
efficacy	I:C0600564
and	O
HRQoL	O
had	O
improved	O
in	O
persons	O
with	O
relapsing	B:C0751967
remitting	I:C0751967
MS	I:C0751967
(	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
)	O
.	O

In	O
a	O
previous	O
study	O
we	O
observed	O
that	O
6	O
months	O
after	O
an	O
intensive	O
3	O
-	O
day	O
social	O
cognitive	O
treatment	I:C0009244
(	O
Can	O
Do	O
treatment	O
)	O
with	O
the	O
participation	O
of	O
support	O
partners	O
,	O
self	O
-	I:C0600564
efficacy	I:C0600564
and	O
HRQoL	O
had	O
improved	O
in	O
persons	O
with	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
(	O
relapsing	B:C0751967
remitting	I:C0751967
MS	I:C0751967
)	O
.	O

Do	O
treatment	O
was	O
given	O
to	O
60	O
persons	B:C0027361
with	O
multiple	O
sclerosis	I:C0026769
and	O
their	O
support	O
partners	O
.	O

Do	O
treatment	O
was	O
given	O
to	O
60	O
persons	O
with	O
multiple	B:C0026769
sclerosis	I:C0026769
and	O
their	O
support	O
partners	O
.	O

Do	O
treatment	O
was	O
given	O
to	O
60	O
persons	O
with	O
multiple	O
sclerosis	I:C0026769
and	O
their	O
support	O
partners	B:C3887537
.	O

At	O
baseline	O
and	O
12	O
months	O
after	O
treatment	B:C0087111
self	O
-	I:C0600564
efficacy	I:C0600564
control	O
,	O
self	O
-	I:C0600564
efficacy	I:C0600564
function	O
,	O
physical	O
and	O
mental	O
HRQoL	O
,	O
anxiety	O
,	O
depression	O
and	O
fatigue	O
were	O
assessed	O
via	O
self	O
-	I:C2700446
report	I:C2700446
questionnaires	O
.	O

At	O
baseline	O
and	O
12	O
months	O
after	O
treatment	O
self	B:C0600564
-	I:C0600564
efficacy	I:C0600564
control	O
,	O
self	O
-	I:C0600564
efficacy	I:C0600564
function	O
,	O
physical	O
and	O
mental	O
HRQoL	O
,	O
anxiety	O
,	O
depression	O
and	O
fatigue	O
were	O
assessed	O
via	O
self	O
-	I:C2700446
report	I:C2700446
questionnaires	O
.	O

At	O
baseline	O
and	O
12	O
months	O
after	O
treatment	O
self	O
-	I:C0600564
efficacy	I:C0600564
control	O
,	O
self	B:C0600564
-	I:C0600564
efficacy	I:C0600564
function	O
,	O
physical	O
and	O
mental	O
HRQoL	O
,	O
anxiety	O
,	O
depression	O
and	O
fatigue	O
were	O
assessed	O
via	O
self	O
-	I:C2700446
report	I:C2700446
questionnaires	O
.	O

At	O
baseline	O
and	O
12	O
months	O
after	O
treatment	O
self	O
-	I:C0600564
efficacy	I:C0600564
control	O
,	O
self	O
-	I:C0600564
efficacy	I:C0600564
function	O
,	O
physical	O
and	O
mental	B:C0025353
HRQoL	O
,	O
anxiety	O
,	O
depression	O
and	O
fatigue	O
were	O
assessed	O
via	O
self	O
-	I:C2700446
report	I:C2700446
questionnaires	O
.	O

At	O
baseline	O
and	O
12	O
months	O
after	O
treatment	O
self	O
-	I:C0600564
efficacy	I:C0600564
control	O
,	O
self	O
-	I:C0600564
efficacy	I:C0600564
function	O
,	O
physical	O
and	O
mental	O
HRQoL	O
,	O
anxiety	B:C0003467
,	O
depression	O
and	O
fatigue	O
were	O
assessed	O
via	O
self	O
-	I:C2700446
report	I:C2700446
questionnaires	O
.	O

At	O
baseline	O
and	O
12	O
months	O
after	O
treatment	O
self	O
-	I:C0600564
efficacy	I:C0600564
control	O
,	O
self	O
-	I:C0600564
efficacy	I:C0600564
function	O
,	O
physical	O
and	O
mental	O
HRQoL	O
,	O
anxiety	O
,	O
depression	B:C0011570
and	O
fatigue	O
were	O
assessed	O
via	O
self	O
-	I:C2700446
report	I:C2700446
questionnaires	O
.	O

At	O
baseline	O
and	O
12	O
months	O
after	O
treatment	O
self	O
-	I:C0600564
efficacy	I:C0600564
control	O
,	O
self	O
-	I:C0600564
efficacy	I:C0600564
function	O
,	O
physical	O
and	O
mental	O
HRQoL	O
,	O
anxiety	O
,	O
depression	O
and	O
fatigue	B:C0015672
were	O
assessed	O
via	O
self	O
-	I:C2700446
report	I:C2700446
questionnaires	O
.	O

At	O
baseline	O
and	O
12	O
months	O
after	O
treatment	O
self	O
-	I:C0600564
efficacy	I:C0600564
control	O
,	O
self	O
-	I:C0600564
efficacy	I:C0600564
function	O
,	O
physical	O
and	O
mental	O
HRQoL	O
,	O
anxiety	O
,	O
depression	O
and	O
fatigue	O
were	O
assessed	O
via	O
self	B:C2700446
-	I:C2700446
report	I:C2700446
questionnaires	O
.	O

At	O
baseline	O
and	O
12	O
months	O
after	O
treatment	O
self	O
-	I:C0600564
efficacy	I:C0600564
control	O
,	O
self	O
-	I:C0600564
efficacy	I:C0600564
function	O
,	O
physical	O
and	O
mental	O
HRQoL	O
,	O
anxiety	O
,	O
depression	O
and	O
fatigue	O
were	O
assessed	O
via	O
self	O
-	I:C2700446
report	I:C2700446
questionnaires	B:C0034394
.	O

Differences	O
were	O
tested	O
via	O
a	O
paired	B:C1709451
t	I:C1709451
test	I:C1709451
.	O

Of	O
the	O
57	O
persons	B:C0027361
with	O
multiple	O
sclerosis	I:C0026769
that	O
completed	O
the	O
baseline	O
assessment	O
and	O
the	O
3	O
-	O
day	O
treatment	O
,	O
38	O
filled	O
in	O
the	O
12th	O
month	O
questionnaires	O
(	O
response	O
rate	O
66.7	O
%	O
)	O
,	O
22	O
with	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
and	O
14	O
with	O
progressive	O
multiple	O
sclerosis	I:C0026769
.	O

Of	O
the	O
57	O
persons	O
with	O
multiple	B:C0026769
sclerosis	I:C0026769
that	O
completed	O
the	O
baseline	O
assessment	O
and	O
the	O
3	O
-	O
day	O
treatment	O
,	O
38	O
filled	O
in	O
the	O
12th	O
month	O
questionnaires	O
(	O
response	O
rate	O
66.7	O
%	O
)	O
,	O
22	O
with	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
and	O
14	O
with	O
progressive	O
multiple	O
sclerosis	I:C0026769
.	O

Of	O
the	O
57	O
persons	O
with	O
multiple	O
sclerosis	I:C0026769
that	O
completed	O
the	O
baseline	O
assessment	O
and	O
the	O
3	O
-	O
day	O
treatment	O
,	O
38	O
filled	O
in	O
the	O
12th	O
month	O
questionnaires	B:C0034394
(	O
response	O
rate	O
66.7	O
%	O
)	O
,	O
22	O
with	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
and	O
14	O
with	O
progressive	O
multiple	O
sclerosis	I:C0026769
.	O

Of	O
the	O
57	O
persons	O
with	O
multiple	O
sclerosis	I:C0026769
that	O
completed	O
the	O
baseline	O
assessment	O
and	O
the	O
3	O
-	O
day	O
treatment	O
,	O
38	O
filled	O
in	O
the	O
12th	O
month	O
questionnaires	O
(	O
response	B:C1704632
rate	O
66.7	O
%	O
)	O
,	O
22	O
with	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
and	O
14	O
with	O
progressive	O
multiple	O
sclerosis	I:C0026769
.	O

Of	O
the	O
57	O
persons	O
with	O
multiple	O
sclerosis	I:C0026769
that	O
completed	O
the	O
baseline	O
assessment	O
and	O
the	O
3	O
-	O
day	O
treatment	O
,	O
38	O
filled	O
in	O
the	O
12th	O
month	O
questionnaires	O
(	O
response	O
rate	O
66.7	O
%	O
)	O
,	O
22	O
with	O
relapsing	B:C0751967
remitting	I:C0751967
MS	I:C0751967
and	O
14	O
with	O
progressive	O
multiple	O
sclerosis	I:C0026769
.	O

Of	O
the	O
57	O
persons	O
with	O
multiple	O
sclerosis	I:C0026769
that	O
completed	O
the	O
baseline	O
assessment	O
and	O
the	O
3	O
-	O
day	O
treatment	O
,	O
38	O
filled	O
in	O
the	O
12th	O
month	O
questionnaires	O
(	O
response	O
rate	O
66.7	O
%	O
)	O
,	O
22	O
with	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
and	O
14	O
with	O
progressive	O
multiple	B:C0026769
sclerosis	I:C0026769
.	O

In	O
the	O
RR	B:C0751967
group	O
self	O
-	I:C0600564
efficacy	I:C0600564
control	O
had	O
increased	O
by	O
20.2	O
%	O
and	O
physical	O
HRQoL	O
by	O
15.0	O
%	O
,	O
and	O
depression	O
and	O
anxiety	O
had	O
decreased	O
by	O
29.8	O
and	O
25.9	O
%	O
,	O
respectively	O
(	O
all	O
P	O
<	O
0.05	O
)	O
;	O
the	O
changes	O
in	O
mental	O
HRQoL	O
(	O
+17	O
%	O
)	O
and	O
fatigue	O
(	O
-	O
20	O
%	O
)	O
failed	O
to	O
be	O
statistically	O
significant	O
(	O
P	O
=	O
0.087	O
,	O
P	O
=	O
0.080	O
,	O
respectively	O
)	O
.	O

In	O
the	O
RR	O
group	O
self	B:C0600564
-	I:C0600564
efficacy	I:C0600564
control	O
had	O
increased	O
by	O
20.2	O
%	O
and	O
physical	O
HRQoL	O
by	O
15.0	O
%	O
,	O
and	O
depression	O
and	O
anxiety	O
had	O
decreased	O
by	O
29.8	O
and	O
25.9	O
%	O
,	O
respectively	O
(	O
all	O
P	O
<	O
0.05	O
)	O
;	O
the	O
changes	O
in	O
mental	O
HRQoL	O
(	O
+17	O
%	O
)	O
and	O
fatigue	O
(	O
-	O
20	O
%	O
)	O
failed	O
to	O
be	O
statistically	O
significant	O
(	O
P	O
=	O
0.087	O
,	O
P	O
=	O
0.080	O
,	O
respectively	O
)	O
.	O

In	O
the	O
RR	O
group	O
self	O
-	I:C0600564
efficacy	I:C0600564
control	O
had	O
increased	O
by	O
20.2	O
%	O
and	O
physical	O
HRQoL	O
by	O
15.0	O
%	O
,	O
and	O
depression	B:C0011570
and	O
anxiety	O
had	O
decreased	O
by	O
29.8	O
and	O
25.9	O
%	O
,	O
respectively	O
(	O
all	O
P	O
<	O
0.05	O
)	O
;	O
the	O
changes	O
in	O
mental	O
HRQoL	O
(	O
+17	O
%	O
)	O
and	O
fatigue	O
(	O
-	O
20	O
%	O
)	O
failed	O
to	O
be	O
statistically	O
significant	O
(	O
P	O
=	O
0.087	O
,	O
P	O
=	O
0.080	O
,	O
respectively	O
)	O
.	O

In	O
the	O
RR	O
group	O
self	O
-	I:C0600564
efficacy	I:C0600564
control	O
had	O
increased	O
by	O
20.2	O
%	O
and	O
physical	O
HRQoL	O
by	O
15.0	O
%	O
,	O
and	O
depression	O
and	O
anxiety	B:C0003467
had	O
decreased	O
by	O
29.8	O
and	O
25.9	O
%	O
,	O
respectively	O
(	O
all	O
P	O
<	O
0.05	O
)	O
;	O
the	O
changes	O
in	O
mental	O
HRQoL	O
(	O
+17	O
%	O
)	O
and	O
fatigue	O
(	O
-	O
20	O
%	O
)	O
failed	O
to	O
be	O
statistically	O
significant	O
(	O
P	O
=	O
0.087	O
,	O
P	O
=	O
0.080	O
,	O
respectively	O
)	O
.	O

In	O
the	O
RR	O
group	O
self	O
-	I:C0600564
efficacy	I:C0600564
control	O
had	O
increased	O
by	O
20.2	O
%	O
and	O
physical	O
HRQoL	O
by	O
15.0	O
%	O
,	O
and	O
depression	O
and	O
anxiety	O
had	O
decreased	O
by	O
29.8	O
and	O
25.9	O
%	O
,	O
respectively	O
(	O
all	O
P	O
<	O
0.05	O
)	O
;	O
the	O
changes	O
in	O
mental	B:C0025353
HRQoL	O
(	O
+17	O
%	O
)	O
and	O
fatigue	O
(	O
-	O
20	O
%	O
)	O
failed	O
to	O
be	O
statistically	O
significant	O
(	O
P	O
=	O
0.087	O
,	O
P	O
=	O
0.080	O
,	O
respectively	O
)	O
.	O

In	O
the	O
RR	O
group	O
self	O
-	I:C0600564
efficacy	I:C0600564
control	O
had	O
increased	O
by	O
20.2	O
%	O
and	O
physical	O
HRQoL	O
by	O
15.0	O
%	O
,	O
and	O
depression	O
and	O
anxiety	O
had	O
decreased	O
by	O
29.8	O
and	O
25.9	O
%	O
,	O
respectively	O
(	O
all	O
P	O
<	O
0.05	O
)	O
;	O
the	O
changes	O
in	O
mental	O
HRQoL	O
(	O
+17	O
%	O
)	O
and	O
fatigue	B:C0015672
(	O
-	O
20	O
%	O
)	O
failed	O
to	O
be	O
statistically	O
significant	O
(	O
P	O
=	O
0.087	O
,	O
P	O
=	O
0.080	O
,	O
respectively	O
)	O
.	O

The	O
findings	O
suggest	O
that	O
a	O
3	O
-	O
day	O
intensive	O
social	O
cognitive	B:C0009244
treatment	I:C0009244
(	O
Can	O
Do	O
treatment	O
)	O
with	O
the	O
participation	O
of	O
support	O
partners	O
may	O
have	O
long	O
lasting	O
beneficial	O
effects	O
on	O
the	O
self	O
-	I:C0600564
efficacy	I:C0600564
and	O
HRQoL	O
in	O
persons	O
with	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
;	O
and	O
that	O
improvements	O
in	O
anxiety	O
and	O
depression	O
,	O
not	O
seen	O
in	O
the	O
6	O
-	O
month	O
study	O
,	O
may	O
yet	O
develop	O
at	O
12	O
months	O
.	O

The	O
findings	O
suggest	O
that	O
a	O
3	O
-	O
day	O
intensive	O
social	O
cognitive	O
treatment	I:C0009244
(	O
Can	O
Do	O
treatment	O
)	O
with	O
the	O
participation	O
of	O
support	O
partners	B:C3887537
may	O
have	O
long	O
lasting	O
beneficial	O
effects	O
on	O
the	O
self	O
-	I:C0600564
efficacy	I:C0600564
and	O
HRQoL	O
in	O
persons	O
with	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
;	O
and	O
that	O
improvements	O
in	O
anxiety	O
and	O
depression	O
,	O
not	O
seen	O
in	O
the	O
6	O
-	O
month	O
study	O
,	O
may	O
yet	O
develop	O
at	O
12	O
months	O
.	O

The	O
findings	O
suggest	O
that	O
a	O
3	O
-	O
day	O
intensive	O
social	O
cognitive	O
treatment	I:C0009244
(	O
Can	O
Do	O
treatment	O
)	O
with	O
the	O
participation	O
of	O
support	O
partners	O
may	O
have	O
long	O
lasting	O
beneficial	O
effects	O
on	O
the	O
self	B:C0600564
-	I:C0600564
efficacy	I:C0600564
and	O
HRQoL	O
in	O
persons	O
with	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
;	O
and	O
that	O
improvements	O
in	O
anxiety	O
and	O
depression	O
,	O
not	O
seen	O
in	O
the	O
6	O
-	O
month	O
study	O
,	O
may	O
yet	O
develop	O
at	O
12	O
months	O
.	O

The	O
findings	O
suggest	O
that	O
a	O
3	O
-	O
day	O
intensive	O
social	O
cognitive	O
treatment	I:C0009244
(	O
Can	O
Do	O
treatment	O
)	O
with	O
the	O
participation	O
of	O
support	O
partners	O
may	O
have	O
long	O
lasting	O
beneficial	O
effects	O
on	O
the	O
self	O
-	I:C0600564
efficacy	I:C0600564
and	O
HRQoL	O
in	O
persons	B:C0027361
with	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
;	O
and	O
that	O
improvements	O
in	O
anxiety	O
and	O
depression	O
,	O
not	O
seen	O
in	O
the	O
6	O
-	O
month	O
study	O
,	O
may	O
yet	O
develop	O
at	O
12	O
months	O
.	O

The	O
findings	O
suggest	O
that	O
a	O
3	O
-	O
day	O
intensive	O
social	O
cognitive	O
treatment	I:C0009244
(	O
Can	O
Do	O
treatment	O
)	O
with	O
the	O
participation	O
of	O
support	O
partners	O
may	O
have	O
long	O
lasting	O
beneficial	O
effects	O
on	O
the	O
self	O
-	I:C0600564
efficacy	I:C0600564
and	O
HRQoL	O
in	O
persons	O
with	O
relapsing	B:C0751967
remitting	I:C0751967
MS	I:C0751967
;	O
and	O
that	O
improvements	O
in	O
anxiety	O
and	O
depression	O
,	O
not	O
seen	O
in	O
the	O
6	O
-	O
month	O
study	O
,	O
may	O
yet	O
develop	O
at	O
12	O
months	O
.	O

The	O
findings	O
suggest	O
that	O
a	O
3	O
-	O
day	O
intensive	O
social	O
cognitive	O
treatment	I:C0009244
(	O
Can	O
Do	O
treatment	O
)	O
with	O
the	O
participation	O
of	O
support	O
partners	O
may	O
have	O
long	O
lasting	O
beneficial	O
effects	O
on	O
the	O
self	O
-	I:C0600564
efficacy	I:C0600564
and	O
HRQoL	O
in	O
persons	O
with	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
;	O
and	O
that	O
improvements	O
in	O
anxiety	B:C0003467
and	O
depression	O
,	O
not	O
seen	O
in	O
the	O
6	O
-	O
month	O
study	O
,	O
may	O
yet	O
develop	O
at	O
12	O
months	O
.	O

The	O
findings	O
suggest	O
that	O
a	O
3	O
-	O
day	O
intensive	O
social	O
cognitive	O
treatment	I:C0009244
(	O
Can	O
Do	O
treatment	O
)	O
with	O
the	O
participation	O
of	O
support	O
partners	O
may	O
have	O
long	O
lasting	O
beneficial	O
effects	O
on	O
the	O
self	O
-	I:C0600564
efficacy	I:C0600564
and	O
HRQoL	O
in	O
persons	O
with	O
relapsing	O
remitting	I:C0751967
MS	I:C0751967
;	O
and	O
that	O
improvements	O
in	O
anxiety	O
and	O
depression	B:C0011570
,	O
not	O
seen	O
in	O
the	O
6	O
-	O
month	O
study	O
,	O
may	O
yet	O
develop	O
at	O
12	O
months	O
.	O

